Elsevier

Vaccine

Volume 28, Issue 31, 12 July 2010, Pages 4970-4976
Vaccine

Cross-clade immunity in cats vaccinated with a canarypox-vectored avian influenza vaccine

https://doi.org/10.1016/j.vaccine.2010.05.028Get rights and content

Abstract

Several felid species have been shown to be susceptible to infection with highly pathogenic avian influenza (HPAI) viruses of the H5N1 subtype. Infection of felids by H5N1 HPAI virus is often fatal, and cat-to-cat transmission has been documented. Domestic cats may then be involved in the transmission of infection to other animals but also to humans. A particular concern is the hypothetical role of the cat in the adaptation of the virus to mammalian species, thus increasing the pandemic risk. Therefore, the development of a HPAI vaccine for domestic cats should be considered a veterinary and also a public health priority. Here we show that vaccination of cats with a recombinant canarypox (ALVAC®1) virus, expressing the hemagglutinin (HA) of influenza virus A/chicken/Indonesia/03 (H5N1) confers protection against challenge infection with two antigenically distinct H5N1 virus isolates from humans. Despite low hemagglutination inhibiting (HI) antibody titers at the time of challenge, all vaccinated cats were protected against mortality and had reduced histopathological changes in the lungs. Importantly, viral shedding was reduced in vaccinated cats as compared to controls, suggesting that vaccination of cats could reduce the risk of viral transmission. In conclusion this study showed that the recombinant canarypox virus protected cats against homologous and heterologous H5N1 HPAI virus challenges.

Introduction

The unprecedented spread of highly pathogenic avian influenza (HPAI) A virus of the H5N1 subtype throughout southeast Asia, Europe, the Middle East and Africa since the mid-nineties, leading to huge morbidity and mortality among domestic and wild birds, has also led to infection in many mammalian species including humans and several carnivore species. More than 450 severe human cases have been reported with a case fatality rate of approximately 60% [1] and a substantial number of outbreaks of H5N1 with high mortality have been documented in felids, including tigers and domestic cats [2]. Like other influenza A virus subtypes, HPAI H5N1 viruses continuously evolve through antigenic drift, at a rate that is alarmingly higher than for the predominant seasonal human variants (H3N2 and H1N1). Today, two different clades (clades 1 and 2), and several lineages within these clades of H5N1 have been identified which predominate in distinct geographic locations [3]. Clade 1 viruses have been isolated in Vietnam, Thailand, Cambodia and Malaysia, while clade 2 viruses of different subclades have caused outbreaks in Indonesia and China, but also in Europe, the Middle East and West Africa. Both clades have been shown to infect felids in the field, and in an experimental setting, challenge of domestic cats with a HPAI H5N1 virus (clade 1) isolated from a human case in Vietnam led to a severe generalized infection. In these experiments, cat-to cat transmission was also documented [4]. These observations suggest that domestic cats may be involved in the transmission of the virus to other animals and to humans. Cats might also play a role in the adaptation of the virus to mammalian species, contributing to the pandemic risk [5]. Therefore, the development of a HPAI vaccine for domestic cats should be considered a veterinary and also a public health priority.

In this study, we tested a recombinant canarypox virus (ALVAC®) expressing the hemagglutinin (HA) of influenza virus A/chicken/Indonesia/03 (H5N1) in a HPAI H5N1 virus vaccination-challenge model in cats. ALVAC recombinant vaccines have been shown to induce protective immune responses against several infectious agents [6]. The canarypox virus vector has two important natural properties: it is a non-replicative vector for mammalian species [7], and anti-vector immunity has not been shown to interfere with the efficacy of subsequent booster vaccination with the same vector [8], at least, in veterinary vaccine development efforts.

Following two doses of the ALVAC H5N1 vaccine candidate, all vaccinated cats were effectively protected against intratracheal challenge with wild-type influenza virus A/Vietnam/1194/2004 (H5N1, clade 1) and A/Indonesia/05/2005 (H5N1, clade 2.1).

Section snippets

Cats

Twenty-four specific pathogen-free European short-hair cats were purchased from Charles River Laboratories, France. They were approximately 4 or 5 months old at the time of the first vaccine injection, and all were seronegative for influenza virus type A and B.

Two weeks before vaccination, a body temperature probe (Star-Oddi, Reykjavik, Iceland) was implanted into the peritoneal cavity of each animal. Before challenge, the animals were housed in groups of four or five. After challenge, the

Vaccine-induced HI antibody response

Fourteen days after the first injection of vCP2241, 6 of the 12 vaccinated cats seroconverted against A/chicken/Indonesia/7/03, and none against A/Vietnam/1194/04. Fourteen days after the second injection of vCP2241, all cats had HI titers against A/chicken/Indonesia/7/03, ranging from 1.2 to 2.4 log10 HI units/mL, and 4 out of 12 cats had low antibody titers against A/Vietnam/1194/04 (Table 1).

Clinical signs (Table 2)

Two controls were found dead on day 4 and 6 post-infection (p.i.). Two other controls were moribund and

Discussion

In this study, the efficacy of a canarypox-vectored vaccine expressing the HA of a highly pathogenic H5N1 strain was tested against homologous and heterologous HPAI virus (HPAIV) challenges in cats. Heterologous challenge was done with A/Vietnam/1194/2004, a HPAIV from a different clade, which has been shown to be highly virulent in cats [12].

Infection with the A/Vietnam/1194/2004 strain or the A/Indonesia/05/2005 strain resulted in severe lethargy, fever, anorexia, weight loss, severe

References (34)

  • M.T. Le et al.

    Influenza A H5N1 clade 2.3.4 virus with a different antiviral susceptibility profile replaced clade 1 virus in humans in northern Vietnam

    PLoS One

    (2008)
  • T. Kuiken et al.

    Avian H5N1 influenza in cats

    Science

    (2004)
  • T. Kuiken et al.

    Feline friend or potential foe?

    Nature

    (2006)
  • S.A. Plotkin et al.

    The safety and use of canarypox vectored vaccines

    Dev Biol Stand

    (1995)
  • D.E. Swayne et al.

    Avian Influenza

  • J.H. Kreijtz et al.

    Recombinant modified vaccinia virus Ankara-based vaccine induces protective immunity in mice against infection with influenza virus H5N1

    J Infect Dis

    (2007)
  • C. Ruat et al.

    Vaccination of macaques with adjuvanted formalin-inactivated influenza A virus (H5N1) vaccines: protection against H5N1 challenge without disease enhancement

    J Virol

    (2008)
  • Cited by (5)

    • Carbohydrate fatty acid monosulphate esters are safe and effective adjuvants for humoral responses

      2017, Vaccine
      Citation Excerpt :

      Antibody responses to H7N9 in ferrets were determined by Viroclinics Biosciences BV (Rotterdam, the Netherlands) as described elsewhere [19]. Briefly, serum samples were pre-treated with cholera filtrate resulting in a pre-dilution of 1:6 and serially two-fold dilutions were tested in the HAI test using 2:6 reassortant (A/Anhui/1/2013 H7N9 and A/PR/8/34) as described elsewhere [20]. Rectal body temperature of rabbits was measured 6 h before and 3 or 6, 24, 48 and 96 h after each immunization.

    • Viral vector-based influenza vaccines

      2016, Human Vaccines and Immunotherapeutics
    1

    ALVAC® is a registered trademark of Connaught Technology Corporation in the United States of America.

    View full text